Baseline characteristics | Study population n = 678 | ||
---|---|---|---|
Sex: male n (%) | 313 (46.2) | ||
Age: median (IQR) | 46 (26, 60) | ||
BMI, median (IQR) | 26.0 (22.9, 30.6) | ||
Rhinitis diagnosis or therapy, n (%) | 305 (45.0) | ||
Smoking status, n (%) | Current Smoker | 40 (5.9) | |
 | Ex-smoker | 145 (21.4) | |
 | Non-smoker | 477 (70.4) | |
Exacerbations, n (%) | 0 | 551 (81.3) | |
 | 1 | 83 (12.2) | |
 | ≥2 | 44 (6.5) | |
SABA dose (mcg), n (%) | 1-100 | 121 (17.8) | |
 | 101-200 | 132 (19.5) | |
 | 201-400 | 94 (13.9) | |
 | 401+ | 47 (6.9) | |
Average ICS Daily dose, (mcg) BDP-equivalent dose, n (%) | None | 304 (44.8) | |
 | 1-100 | 67 (9.9) | |
 | 101-200 | 106 (15.6) | |
 | 201-400 | 101 (14.9) | |
 | 401+ | 100 (14.7) | |
Asthma therapy, n (%) | None | 193 (28.5) | |
 | SABA | 101 (14.9) | |
 | ±SABA | LTRA | 8 (1.2%) |
 |  | ICS | 182 (26.8) |
 |  | ICS + LABA | 136 (20.1) |
 |  | ICS + LAMA | 1 (0.1) |
 | ±SAMA | ICS + LABA + LAMA | 5 (0.7) |
 |  | ICS + LTRA | 8 (1.2) |
 |  | ICS + LABA + LTRA | 42 (6.2) |
 | Other | 2 (0.3) |